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Chronic lymphocytic leukemia (CLL) is a malignant lymphoproliferative disorder
of monoclonal B lymphocytes that accumulate in the blood, bone marrow, lymph
nodes and other lymphoid tissues.1,2 It represents the most common adult leukemia
in the western world, mainly affecting elderly individuals. Although the progres-
sion-free survival (PFS) and overall survival (OS) of CLL patients have increased
with the introduction of first-line therapy, there is no cure for CLL and all patients
will ultimately relapse. The standard of treatment for physically fit patients is
chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR),3
and for older patients bendamustine plus rituximab may be a better option.4
Relapsed patients or those with altered TP53 can be treated with the bruton tyro-
sine kinase (BTK) inhibitor ibrutinib, and also with the phosphoinositide 3-kinase
(PI3K) inhibitor idelalisib or the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax
(ABT-199).5 Recently, ibrutinib has been approved to treat CLL patients in first-line
therapy.5 Nevertheless, a percentage of patients are resistant to ibrutinib or do not
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ABSTRACT
tolerate the drug.6-9 Therefore, it is necessary to identify
new agents with selective toxicity for malignant B cells
and to develop therapeutic strategies that can overcome
cellular resistance mechanisms to current therapies, that
can overcome cellular resistance mechanisms to current
therapies. Hence, the nucleoside analogue 5-aminoimida-
zole-4-carboxamide riboside (AICAR) induces apoptosis
in CLL cells independently of p53 status.10
Recently, our group has described novel pro-apoptotic
small molecules with fluorinated thiazole scaffolds.11 The
diaryl trifluorothiazoline compound 1a, also termed fluo-
rizoline (Figure 1A), was selected as the best apoptosis
inductor in a wide range of cancer cell lines from different
tissue origin, including hematopoietic cell lines, and differ-
ent p53 status, proving that fluorizoline exerts its anti-
tumor action in a p53-independent manner. Fluorizoline
selectively binds to prohibitin (PHB) 1 and 211 and, strik-
ingly, these proteins are necessary for apoptosis induction
by this compound.12 Fluorizoline treatment induces mito-
chondrial-mediated apoptosis, a pathway that is con-
trolled by the BCL-2 family proteins. In this regard, induc-
tion of the pro-apoptotic protein NOXA is required for
fluorizoline-induced apoptosis, and BIM is also involved
depending on the cellular context.12
Prohibitins are ubiquitous, evolutionarily conserved
scaffold proteins mainly localized in mitochondria and
implicated in many cellular processes, including mito-
chondrial biogenesis, differentiation, cell survival and
apoptosis. Two highly homologous proteins, PHB1 and
PHB2/REA, have been described.13,14 Increasing evidence
links PHBs and tumorigenesis.15,16
In B lymphocytes, PHBs were identified as proteins
associated with the immunoglobulin M (IgM) B cell recep-
tor (BCR).17 More recently, PHBs were described as pro-
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Figure 1. Cytotoxicity of fluorizoline in CLL cells
ex vivo. (A) Chemical structure of fluorizoline. (B)
Dose response of fluorizoline on primary CLL
cells. PBMNC from 5 representative untreated
CLL patients (#6, 9, 12, 14 and 29) out of 34
were incubated for 24 h with increasing doses of
fluorizoline ranging from 1.25 to 10 µM. (C)
PBMNC from 34 CLL patients were incubated for
24 h with or without 10 µM fluorizoline. (D) Time
course of fluorizoline-induced apoptosis in CLL
cells. Cells from 5 patients were untreated or
incubated for different times ranging from 2 to 24
h with 10 mM fluorizoline. (E) Dose response of
the cytotoxic effect of fluorizoline on B and T cells
from CLL patients. PBMNC from CLL patients
were incubated for 24 h with increasing doses of
fluorizoline ranging from 1.25 to 10 mM. Viability
was measured on CD3+ (T cells, n=15) and CD19+
(B cells, n=34) populations. (F) Dose response of
the cytotoxic effect of fluorizoline on normal B
and T cells. PBMNC from 12 healthy donors were
incubated for 24 h with increasing doses of fluo-
rizoline ranging from 1.25 to 10 mM. Viability was
measured on CD3+ (T cells) and CD19+ (B cells)
populations. (B, C, D, E and F) Viability (annexin V
negative) was measured by analysis of phos-
phatidylserine exposure in total population or in
CD19+ and CD3+ populations and is expressed (B
and C) as the percentage of non-apoptotic cells or
(D, E and F) as the percentage of the viability of
untreated cells. (D, E and F) Data are shown as
the mean±SEM. (D) Two-tailed paired Student’s 
t-test was performed. (E and F) Two-tailed
unpaired Student’s t-test was performed.
Significant P values are indicated: *P<0.05;
**P<0.01; ***P<0.001 treated versus untreat-
ed cells or CD19+ versus CD3+ cells.
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teins associated with phosphorylated protein tyrosine
kinase Syk18 and the receptor CD8619 at the inner plasma
membranes of B lymphocytes, thus likely having a role in
signal transduction after receptor engagement. In CLL
cells, PHB is increased after phorbol ester-induced matura-
tion,20 and nuclear PHB is upregulated after in vitro treat-
ment with fludarabine.21 These data strongly suggest that
targeting PHBs would be a candidate approach for the
treatment of B-cell neoplasias, and PHB-binding com-
pounds, such as fluorizoline, emerge as interesting new
pro-apoptotic agents. Preliminary data in a small number
of CLL samples showed that fluorizoline induces apopto-
sis in these cells.11 The objective of the work herein was to
investigate the mechanism of induction of apoptosis by
fluorizoline in CLL cells and the effect of its combination
with ibrutinib, AICAR or venetoclax.
Methods
Primary samples and cell isolation
Peripheral blood (PB) samples from 34 untreated patients with
CLL and 12 healthy donors were included. All patients and
healthy controls signed an informed consent form approved by
the Institutional Review Boards according to the Declaration of
Helsinki. The patients’ characteristics are shown in Online
Supplementary Table S1. Briefly, PB mononuclear cells (PBMNC)
were obtained by centrifugation on a Biocoll gradient. This frac-
tion included normal B and T cells from healthy donors or mainly
B-CLL cells from patients. To ensure high B cell purity (≥80%), an
initial isolation step was performed by negative selection. The
complete sample handling protocol is available in the Online
Supplementary Data.
Reagents
Fluorizoline (a diaryl trifluorothiazoline; see molecular structure
in Figure 1A) was synthesized as previously described.11 Other
reagents used in this study are detailed in the Online Supplementary
Data.
Analysis of cell purity and cell viability by flow 
cytometry
Cell viability was assessed by phosphatidylserine exposure and
measured as the percentage of annexin V negative cell population.
Cells were acquired using the FACSCantoTM II flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA) and the data of total
cells or CD19+- or CD3+-gated cells were analyzed using
FACSDivaTM software (Becton Dickinson). A detailed protocol of
cell staining can be found in the Online Supplementary Data.
Reverse transcriptase multiplex ligation-dependent
probe amplification (RT-MLPA)
Ribonucleic acid (RNA) isolated from cells was analyzed by RT-
MLPA using SALSA MLPA KIT R011-C1 Apoptosis messenger
(m)RNA from MRC-Holland (Amsterdam, The Netherlands) for
the simultaneous detection of 40 mRNA molecules, including
apoptosis-related genes.12,22 The protocol is accurately described in
the Online Supplementary Data.
Western blot
The antibodies used in this study and the western blot protocol
are described in the Online Supplementary Data.
Statistical analysis
Results are shown as the mean ± standard error of the mean
(SEM) of values obtained in 3 or more independent experiments as
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Figure 2. Induction of NOXA protein by fluorizoline in primary CLL cells. (A) PBMNC from patient #11 were incubated for different times ranging from 2 to 24 h with
10 mM fluorizoline. After the times stated on the figure, cells were collected. (B) PBMNC from patients #5, 12, 23 and 29 were incubated with 10 mM fluorizoline for
24 h. (C) PBMNC from patient #5 were pre-incubated with 20 mM caspase inhibitor Q-VD-OPh for 30 min and then treated with 10 mM fluorizoline for 24 h. (D) PBMNC
from patient #8 with 17p deletion were untreated (U) or treated with 5 and 10 mM fluorizoline (F) for 48 h. (A, B, C and D) Cells were lysed and analyzed by western
blot. BCL-2 was used for loading normalization. Viability was measured by analysis of phosphatidylserine exposure and is expressed as the percentage of non-apop-
totic (annexin V negative) cells. These are representative patients of at least 3 analyzed (n=5 for A; n=8 for B; n=4 for C; n=1 for D).
A B
C D
indicated in each figure legend. Data were analyzed using SPSS®
Statistics v22.0 software package (IBM®, Armonk, NY, USA).
Two-tailed paired or unpaired Student’s t-test with normal-based
95% confidence interval was used to compare the differences
between samples, as required. Differences were considered statis-
tically significant at P values below 0.05. In two-drug combination
studies, the combination index (CI) was calculated according to
the Chou-Talalay method23 by using CalcuSyn software version
2.11 (Biosoft, Cambridge, UK). A CI of below 1 indicates a syner-
gistic effect.
Results
Fluorizoline induces apoptosis in primary CLL cells 
ex vivo
The cytotoxicity of fluorizoline (Figure 1A) was evaluat-
ed in samples obtained from patients with CLL prior to
any treatment (see Online Supplementary Table S1 for details
of patient samples). PBMNC from 34 different patients
were exposed ex vivo to a range of fluorizoline concentra-
tions (from 1.25 to 20 mM). Incubation with fluorizoline
strongly reduced cell viability in a dose-dependent manner
(Figure 1B). All CLL samples were sensitive to fluorizoline,
and cell viability decreased from 70.0±1.9% to 28.1±2.6%
(n=34) after incubation with 10 mM fluorizoline for 24
hours (Figure 1C), with half-maximal effective concentra-
tion (EC50) values ranging from 2.5 to 20 mM (mean 8.1±0.6
mM; Online Supplementary Table S1). Longer exposition to
fluorizoline for 48 hours slightly reduced the mean EC50
value to 5.5±0.6 mM (n=25; Online Supplementary Table S1).
Treatment with 10 mM fluorizoline induced a time-depen-
dent decrease of cell viability that was detected after the
first 8 hours of incubation (Figure 1D).
Some patients included in this study harbored alter-
ations of the TP53 and ATM genes detected by fluorescent
in situ hybridization (FISH; Online Supplementary Table S1),
which are associated with poor response to chemothera-
py and chemoimmunotherapy and a worse prognosis.1,2
Interestingly, samples from these patients had similar sen-
sitivity to ex vivo treatment with fluorizoline (mean EC50
value of 8.3±0,5 mM at 24 hours for samples from patients
with 17p or 11q deletion, n=5) compared to samples from
patients without these alterations (mean EC50 value of
8,1±0,8 mM at 24 hours, n=29). Similarly, ex vivo cytotoxi-
city of fluorizoline was similar in cells from CLL patients
with unmutated and mutated immunoglobulin heavy
chain variable region (IGHV) genes (mean EC50 values at
24 hours of 10,0±1,6 mM, n=5; and 10,3±3,5 mM, n=4;
respectively) (Online Supplementary Table S1).
To examine the effects on the non-leukemic T lympho-
cytes of CLL patients, apoptosis induction was assayed in
the CD3+ population of 15 CLL samples. As depicted in
Figure 1E, the reduction in cell viability in the presence of
fluorizoline was higher within the leukemic CD19+ popu-
lation (35.3±34.9% of viable cells at 24 hours treatment
with 10 mM fluorizoline) compared to the normal CD3+
population (83.8±7.5% of viable cells at 24 hours treat-
ment with 10 mM fluorizoline, with EC50 values higher
than 20 mM in 9 samples out of 15), demonstrating that
fluorizoline preferentially induces apoptosis in malignant
B lymphocytes.
Additionally, to evaluate the cytotoxicity of fluorizoline
in non-malignant B cells, the effect of fluorizoline on nor-
mal PBMNC from healthy donors was assessed.
Incubation with increasing doses of fluorizoline reduced
the percentage of viable normal B and T cells (48.6±6.8%
and 82.8±6.3% of viable cells at 24 hours of treatment
with 10 mM fluorizoline in normal CD19+ and CD3+ pop-
ulations, respectively) (Figure 1F) with a mean EC50 value
of 10.9±0.8 mM and 19.1±2.2 mM at 24 hours for normal B
and T cells, respectively. Thus, CLL cells are slightly more
sensitive to fluorizoline than normal B lymphocytes.
NOXA is upregulated by fluorizoline in primary 
CLL cells
To analyze the mechanism of apoptosis induction upon
fluorizoline treatment in B lymphocytes of CLL samples
we sought to examine the changes in the protein levels of
NOXA and BIM, 2 members of the BCL-2 family that
have been involved previously in fluorizoline-induced
apoptosis.12 We observed a time-dependent upregulation
of NOXA that was detected after 8 hours of incubation,
occurring simultaneously with the decrease of cell viabili-
ty (Figure 2A), and was also clearly found upregulated
after 24 hours in all samples analyzed (Figure 2B). The pro-
tein levels of MCL-1, the anti-apoptotic counterpart of
NOXA, were slightly upregulated during the first hours of
incubation with fluorizoline and were not altered after 24
hours. PUMA and BIM, as well as PHBs protein levels,
were not modified upon fluorizoline treatment (Figure
2A). In addition, fluorizoline clearly induced 
poly(ADP-ribose) polymerase (PARP) cleavage (Figure 2A),
thus confirming an apoptotic mechanism. The induction
of NOXA preceded caspase activation, as pre-incubation
with the pan-caspase inhibitor Q-VD-OPh did not block
its upregulation (Figure 2C). As expected, BIM protein
expression was not modified upon caspase inhibition,
whereas MCL-1 protein levels were increased at 24 hours
after caspase activity arrest, both in the absence and the
presence of fluorizoline, indicating a late caspase-depen-
dent degradation of this protein (Figure 2C). Finally, the
increase of NOXA protein expression was also detected in
CLL samples from patients with chromosomal alterations
that cause loss of p53 expression (Figure 2D), thus corrob-
orating the fact that fluorizoline-induced NOXA upregula-
tion occurs in a p53-independent manner. Altogether,
these results indicate that fluorizoline causes an increase
of NOXA protein levels prior to caspase activation and
these modulations could explain the apoptotic outcome
observed in primary CLL cells.
The induction of NOXA protein by fluorizoline could be
due to the modulation of the corresponding mRNA levels.
To that purpose, we analyzed the changes in the overall
apoptosis mRNA expression profile by RT-MLPA. NOXA
levels were not modified after fluorizoline treatment, nei-
ther at the initial stages nor at 24 hours of incubation of
CLL cells (Online Supplementary Figure S1). Among all apop-
tosis-related genes analyzed, only the pro-apoptotic BCL-2
family member MOAP1 and the anti-apoptotic HIAP1 and
HIAP2 were weakly upregulated and downregulated upon
fluorizoline treatment, respectively. This result indicates
that fluorizoline-induced NOXA protein upregulation does
not result from mRNA modulation in CLL cells.
Fluorizoline synergizes with ibrutinib, AICAR or 
venetoclax to induce apoptosis in CLL cells
Finally, we sought to analyze the effect of the combina-
tion of fluorizoline with other drugs. For that purpose we
chose the BTK irreversible inhibitor ibrutinib, the nucleo-
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side analogue AICAR, which has demonstrated selective
anti-tumor activity in CLL ex vivo10,24 and was tested in a
phase I/II clinical trial for relapsed/refractory CLL,25 and
the BCL-2 inhibitor venetoclax (ABT-199). Ibrutinib thera-
py in vivo causes an intracellular MCL-1 protein decrease,26
and partially downregulates MCL-1 protein levels in vitro
in some CLL patient samples.27 Interestingly, the combina-
tion of fluorizoline with ibrutinib was more effective than
single drug treatment in all patients analyzed. Thus, the
addition of ibrutinib enhanced fluorizoline cytotoxic
effect (CI values ranging from 0.192 to 0.797, indicating a
synergistic effect; the lowest CI values correspond to the
combination of fluorizoline with 10 mM ibrutinib) (Figure
3A). Similarly, the combination of fluorizoline with
AICAR increased cell death compared to each drug alone
(CI values ranging from 0.643 to 0.991; the lowest CI val-
ues correspond to the combination of AICAR with 10 mM
fluorizoline) (Figure 3B). Finally, the combination of fluo-
rizoline and venetoclax showed a synergic effect in all
conditions analyzed (CI values ranging from 0.492 to
0.824; the lowest CI values correspond to the combination
of venetoclax with 10 mM fluorizoline) (Figure 3C). Thus,
these results show a synergistic interaction between fluo-
rizoline and ibrutinib, AICAR or venetoclax in CLL cells.
Discussion
In the study herein we describe the mechanism of apop-
tosis induction by the prohibitin-binding compound fluo-
rizoline in CLL cells. It was previously described that flu-
orizoline directly binds to PHB1 and PHB211 and reduces
cell viability through the upregulation of NOXA and
BIM.12 Although PHBs are necessary for apoptosis induc-
tion by fluorizoline,12 we cannot discard that it could inter-
act with other proteins. Expression analysis revealed a
consistent upregulation of the BH3-only protein NOXA in
CLL cells upon fluorizoline treatment. Fluorizoline
induced increases in NOXA protein levels prior to caspase
activation, which could explain the apoptotic outcome.
Formerly, the effects of fluorizoline in primary cancer cells
have been analyzed in cells from patients with chronic
myeloid leukemia in blast crisis, mantle cell lymphoma, B
cell chronic lymphoproliferative syndrome, adult T-cell
leukemia/lymphoma,12 and in acute myeloid leukemia
cells.28 Interestingly, treatment with fluorizoline resulted
in a decrease in viability and an increase in NOXA protein
levels, whereas BIM protein levels were not modified.
Hence, fluorizoline seems to mainly increase NOXA pro-
tein levels in leukemia cells.
NOXA has been described as a particularly relevant pro-
apoptotic BCL-2 family member in CLL cells. NOXA pro-
tein is induced by histone deacetylase (HDAC)
inhibitors,29,30 proteasome inhibitors,31 bendamustine,32
Akt inhibitors,33 AICAR,10 cyclin-dependent kinase
inhibitors34 and microtubule disrupting agents.35
Furthermore, CLL development is accelerated in mice
with a deficiency of NOXA.36 NOXA is a pro-apoptotic
BH3-only member that has been classified as a “sensitizer”
because it was considered as an inhibitor of the anti-apop-
totic MCL-1 and A1 proteins.37 However, recent data indi-
cate that NOXA is also an “activator” of the BAX and BAK
multidomain pro-apoptotic BCL-2 family members.38
Related to our study with a PHB-binding compound in
CLL, rocaglamide silvestrol induces apoptosis of CLL
Targeting PHBs induces apoptosis in CLL cells
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Figure 3. Combination of fluorizoline and other drugs in CLL cells ex vivo. (A)
PBMNC from 5-9 untreated CLL patients (#11, 12, 15, 16, 17, 18, 23, 28 and
30) were incubated for 24 h with increasing doses of fluorizoline ranging from
1.25 to 10 mM and combined with increasing doses of ibrutinib ranging from 1
to 10 mM. (B) PBMNC from 4-5 untreated CLL patients (#5, 11, 17, 18 and 23)
were incubated for 24 h with increasing doses of fluorizoline ranging from 1.25
to 10 mM and combined with increasing doses of 5-aminoimidazole-4-carbox-
amide riboside (AICAR) ranging from 0.125 to 0.5 mM. (C) PBMNC from 5-6
untreated CLL patients (#10, 13, 14, 16, 23 and 25) were incubated for 24 h
with increasing doses of fluorizoline ranging from 1.25 to 10 mM and combined
with increasing doses of venetoclax (ABT-199) ranging from 0.1 to 1 nM.
Viability was measured by analysis of phosphatidylserine exposure and is
expressed as the percentage of the viability (annexin V negative) of untreated
cells. Data are shown as the mean±SEM.
A
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cells.39 Interestingly, some rocaglamides bind to PHB and it
has been described that this binding mediates its anti-pro-
liferative effects through inhibition of the Raf-MEK-ERK
pathway.40 However, whether or not silvestrol binds to
PHB is presently unknown.
Our study has shown that T cells from CLL patients are
less sensitive to fluorizoline-induced apoptosis. Thus, the
differential effect of fluorizoline in B and T lymphocytes is
of great interest and may be useful in the therapy of CLL,
since immunosuppression caused by classic chemothera-
py could be avoided or reduced. In vivo experiments could
be necessary in the future and it is possible that the effec-
tive concentration of fluorizoline would be higher than in
the in vitro conditions. Thus, further testing the effect of
fluorizoline in CLL cells co-cultured with bone marrow
stromal cells would be interesting in order to better repro-
duce the CLL microenvironment conditions.41
Finally, our results show that the combination of fluori-
zoline with ibrutinib, AICAR or venetoclax has synergistic
effects in the induction of apoptosis in CLL cells. Likely
the induction of NOXA by fluorizoline is involved in
these synergistic effects and could overcome resistance to
BCL-2 inhibitors that do not inhibit MCL-1.
Altogether, our results suggest that fluorizoline could be
an alternative therapy for resistant/refractory patients to
classic chemotherapy or novel drugs such as kinase
inhibitors or BCL-2 antagonists approved for the treat-
ment of CLL.
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